Neuroptika

Neuroptika is a clinical-stage biotechnology company founded in November 2018 as a spin-off from Senju Pharmaceutical Co., Ltd., a privately held pharmaceutical company headquartered in Osaka, Japan. Neuroptika is developing NRO-1, a novel therapy capable of protecting and regenerating corneal nerves. NRO-1 has generated compelling data demonstrating accelerated nerve regeneration, which led to the restoration of functional nerves and corneal sensitivity in animal studies. A successful Phase 1 SAD/MAD clinical study has been completed, and a Phase 2 clinical study for dry eye disease was initiated in the second half of 2019. While most treatments for dry eye disease focus on addressing signs and symptoms, NRO-1 has the potential to become the first disease-modifying regenerative treatment. The benefits of NRO-1 are also being studied in other indications, including post-LASIK care, glaucoma, and Leber's hereditary optic neuropathy.